Skip to main content

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Newswire.ca - Thu Mar 5, 8:30AM CST

GAD Therapies Market Set to Explode to $4.26B by 2033 as Demand Rockets for Innovative Anxiety Solutions 

NEW YORK, March 5, 2026 /CNW/ -- Market News UpdatesNews Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news for millions of people dealing with constant worry and stress. Traditional medications like anti-anxiety drugs and antidepressants still play a big role, but therapy options such as cognitive-behavioral therapy and mindfulness techniques are also helping people manage symptoms without relying only on medication. Digital mental health tools and telehealth visits are making treatment easier to access, especially for people who may not have nearby providers or prefer remote care.  Active Companies in the biotech space of interest include: Helus PharmaTM (NASDAQ: HELP) (Cboe CA: HELP), Acadia Healthcare Company, Inc. (NASDAQ: ACHC), Johnson & Johnson (NYSE: JNJ), BrainsWay Ltd. (NASDAQ: BWAY), Firefly Neuroscience, Inc. (NASDAQ: AIFF).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).